Altos Labs, a biotechnology company backed by $3 billion in funding from Jeff Bezos and other investors, has acquired Dorian Therapeutics, a Peninsula-based firm specializing in senoblockers, expanding its pipeline focused on anti-aging therapies. Meanwhile, NewLimit, another biotech startup, has raised $130 million to develop treatments aimed at reversing aging in human cells, with three therapies currently in development targeting the restoration of liver cell function. Additionally, Spanish researchers have identified mechanisms of blood aging, which could pave the way for anti-aging interventions in humans following successful trials in mice.